Dozens of COVID-19 cases have been reported at two veterans care centers in Virginia.
— ABC News: Top Stories
Author: Michelle Dryden
PARSIPPANY, N.J.–(BUSINESS WIRE)–B&G Foods announced today it is voluntarily recalling a very limited number of boxes of a single date code of 6 oz. Back to Nature Organic Rosemary & Olive Oil Stoneground Wheat Crackers, with a “best by” date of APR 25 2021, after learning that a very limited number of the cracker boxes were inadvertently filled with foil wrapped pouches of peanut butter cookies, which contain peanut, an allergen undeclared on the label. People who have an allergy or severe sensitivity to peanut run the risk of serious or life-threatening allergic reaction if they consume the cookies contained in the recalled boxes. There is no health risk associated with this product for individuals without an allergy to peanut.
This recall affects only a very limited number of boxes of the following product, which may have been distributed in retail stores nationwide:
|
Description |
Consumer UPC # |
Size |
Best By Date |
|
Back to Nature Organic Rosemary & Olive Oil Stoneground Wheat Crackers |
8-19898-01015-8 |
6 oz. |
APR 25 2021 (The “best by” date is located on the top of the box.) |
This recall does not apply to any other “best by” dates, sizes or varieties of Back to Nature products.
No allergic reactions related to this matter have been reported to date. This recall was initiated in cooperation with the FDA and the third party co-packer that produced the product.
B&G Foods discovered this issue when it received consumer complaints that the foil bags within two boxes of Back to Nature Organic Rosemary & Olive Oil Stoneground Wheat Crackers contained peanut butter cookies. The foil bags do correctly indicate whether the product contains rosemary & olive oil crackers or peanut butter cookies.
A third party co-packer inadvertently used a small number of Back to Nature Organic Rosemary & Olive Oil Stoneground Wheat Crackers product boxes in connection with a production run of peanut butter cookies. Back to Nature Organic Rosemary & Olive Oil Stoneground Wheat Crackers were not produced on that date. As such, B&G Foods believes this recall impacts only a handful of boxes of Back to Nature Organic Rosemary & Olive Oil Stoneground Wheat Crackers. However, out of an abundance of caution, B&G Foods is issuing this recall for boxes with this particular “best by” date that have been shipped to its customers. Product with this particular “best by” date may have been shipped and distributed by B&G Foods to its customers’ warehouses located in Arizona, California, Colorado, Connecticut, Florida, Georgia, Iowa, Illinois, Indiana, Kansas, Kentucky, Maryland, Maine, North Carolina, New Hampshire, New Jersey, Nevada, New York, Ohio, Pennsylvania, Tennessee, Texas, Washington and Wisconsin.
Consumers who have purchased the recalled product can return it to the place of purchase for a full refund. Consumers seeking a refund or additional information may also contact B&G Foods by calling 855.346.2225 Monday through Friday from 8:30 a.m. to 6:00 p.m. Eastern time or submitting a contact at https://backtonaturefoods.com/contact-us.
Contacts
Media Relations:
ICR, Inc.
Matt Lindberg
203.682.8214
October 10, 2020
Broadway performances are cancelled through May 2021. Touring shows across North American are also affected.
“The Music Man” and other shows will have to plan new opening dates, as a new reality sets in: Many theaters are likely to stay shut through next fall.
— ABC News: Top Stories
— NYT – Top Stories: Michael Paulson
Two brothers who were charged Thursday in a plot to kidnap and kill Michigan Gov. Gretchen Whitmer were identified as the identical twins photographed months earlier during a protest inside the state Capitol carrying long guns.
— FOX News: Vandana Rambaran
Louisiana has been hit particularly hard during the 2020 hurricane season.
— ABC News: Top Stories
A wild animal trainer featured in the popular Netflix series “Tiger King” has been indicted in Virginia on animal cruelty and wildlife trafficking charges.
— ABC News: Top Stories
Categories
Don’t give up on America
This country is not just an idea. It’s a family.
NYT – Top Stories: Marilynne Robinson
New Software Tool Designed to Help Oncologists Improve Patient Outcomes and Achieve Cost-Saving Goals
Available Exclusively through LabCorp and Powered by HealthEC®
BURLINGTON, N.C. & EDISON, N.J.–(BUSINESS WIRE)–LabCorp (NYSE: LH), a leading global life sciences company that is focused on advancing health and guiding patient care decisions, and HealthEC, LLC, a leading provider of population health management solutions, today announced the launch of LabCorp’s Care Intelligence Oncology Module (Oncology Care Module). LabCorp’s Oncology Care Module is designed to empower oncologists to improve patient outcomes and achieve cost-savings by making it easier to access and compare key data points and performance metrics. Available exclusively through LabCorp, the single-platform solution connects claims and clinical systems using the LabCorp Care Intelligence™ application, powered by HealthEC®.
LabCorp’s Oncology Care Module helps oncology practices measure performance against critical quality and cost benchmarks, including value-based care objectives. The solution consolidates clinically relevant patient and practice data points to provide a more detailed, holistic view of each patient. As part of LabCorp’s Care Intelligence application, the Oncology Care Module integrates securely and seamlessly with electronic health records and other practice management tools and systems. It combines clinical, claims, pharmacogenomics, and staging data; genetic and other clinical laboratory test results; and the patient’s Eastern Cooperative Oncology Group Performance status in a format that is easy-to-use for busy physicians.
LabCorp’s Oncology Care Module provides clinicians with real-time access to critical information that can improve patient outcomes, manage costs, and optimize quality-of-life for patients. The solution also supports patient communications with their care team and allows for patient reported outcomes (ePRO) relevant to their care. Access to this data provides a more comprehensive picture of patient status than information captured through clinical visits alone. Additionally, the tool has the ability to identify patients who may qualify to participate in clinical studies of new treatments through Covance, LabCorp’s drug development business, as well as monitor the progress of patients who are participating in a study.
“LabCorp continues to look for more ways to improve outcomes for cancer patients through the unique combination of our capabilities in diagnostics, drug development, and technology,” said Dr. Brian Caveney, president of LabCorp Diagnostics. “Clinicians, patients, and managed care organizations are increasingly relying on data to identify new treatments, improve patient outcomes, and manage costs. Our Oncology Care Module brings together important information to meet those objectives and helps people make more informed decisions.”
“As new technologies transform cancer care, oncology practices need comprehensive support to run their operations efficiently and ensure patients receive quality care in today’s value-based care environment,” said Arthur Kapoor, chairman and chief executive officer at HealthEC. “We’re pleased to extend our collaboration with LabCorp and look forward to helping oncology providers optimize operations with advanced data aggregation and analytics solutions as the healthcare industry transitions from volume to value.”
For more information about the LabCorp Care Intelligence application, please visit https://www.labcorp.com/CareIntelligence.
About HealthEC
HealthEC, LLC, the 2019 Best in KLAS provider of population health management solutions, is on a mission to help its customers succeed with value-based care. HealthEC®, a single-platform solution, enables personalized healthcare by leveraging the power of connectivity and interoperability: connecting claims and clinical systems, enabling data-driven collaboration between payers and providers, and streamlining care coordination across the healthcare landscape. Organizations are empowered with comprehensive analytics and integrated, role-based tools that translate insights into strategies, address care gaps, and improve quality metrics. To learn more, visit us at www.HealthEC.com, Twitter, LinkedIn and Facebook.
About LabCorp
LabCorp (NYSE: LH), an S&P 500 company, is a leading global life sciences company that is deeply integrated in guiding patient care, providing comprehensive clinical laboratory and end-to-end drug development services. With a mission to improve health and improve lives, LabCorp delivers world-class diagnostics solutions, brings innovative medicines to patients faster, and uses technology to improve the delivery of care. LabCorp reported revenue of more than $11.5 billion in 2019.
To learn more about LabCorp, visit www.LabCorp.com, and to learn more about LabCorp’s drug development business, Covance, visit www.Covance.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements, including but not limited to statements with respect to scientific collaborations, customer contracts and relationships, the anticipated benefits of such collaboration and relationships, and the expected impact that the various collaborations and customer relationships may have on the Company’s financial results. Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the Company’s control, including without limitation, the Company’s ability to establish and maintain strategic partnerships and other scientific collaborations, competitive actions in the marketplace, and other unforeseen changes and general uncertainties in the marketplace, changes in government regulations, including healthcare reform, customer purchasing decisions, including changes in payer regulations or policies, adverse actions of governmental and other third-party payers, patient safety issues, changes in testing guidelines or recommendations. These factors, in some cases, have affected and in the future (together with other factors) could affect the Company’s ability to implement the Company’s business strategy and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the Company’s most recent Annual Report on Form 10-K and subsequent Forms 10-Q, including in each case under the heading RISK FACTORS, and in the Company’s other filings with the SEC.
# # #
Contacts
LabCorp Contacts:
Media: Donald Von Hagen — 336-436-8263
Investors: Clarissa Willett — 336-436-5076
HealthEC Contact:
Laura Porto — 732-652-1519
October 9, 2020
New Heads of Small Business Banking, Consumer Lending and new Chief Marketing Officer bring deep experience to accelerate the Bank’s transformation
BOSTON–(BUSINESS WIRE)–Santander Bank, N.A. (“Santander Bank” or “the Bank”) announced today the appointment of three key executives: Patrick Smith has been named Head of Small Business Banking, Giancarlo Marchesi has been named Head of Consumer Lending, and Jennifer Mathissen has been named Chief Marketing Officer. They will report to Head of Consumer and Business Banking Pierre Habis. The appointments are another important step in Santander Bank’s growth and transformation strategy.
“Santander Bank is on a path toward growth through simplifying how we go to market and expanding our digital product offerings,” said Santander US and Santander Bank CEO Tim Wennes. “These leaders will bring a wealth of knowledge and experience to Santander and their talent will be invaluable as we execute against our strategy.”
“I want to welcome Patrick, Giancarlo and Jennifer to Santander,” said Habis. “They are subject matter experts in their fields and having their talent on the team will greatly accelerate the Bank’s transformation. We want to become closer to our customers, and these new leaders will help us build an operating model that matches our customer-first mindset.”
Head of Small Business Banking
Smith joined Santander Bank on October 5, based in Boston, as Head of Small Business Banking. He is responsible for developing the strategic direction, product pricing and portfolio management of the Small Business Banking division.
“Small businesses are the fabric of our economy, and we’re modernizing our banking model to better help small businesses prosper and to serve their holistic financial needs. Patrick will be integral to this transformation to become a premier small business bank,” said Habis.
Smith comes to Santander from KeyBank where he was Executive Vice President and Head of Commercial Digital. Prior to that, Smith was Executive Vice President of Financial Wellness and Consumer Strategy and was responsible for creating and executing the strategy to transform KeyBank’s consumer banking franchise through digital products, financial wellness programs and brand partnerships. He has more than 25 years of experience in the financial services industry. Smith earned a Bachelor of Science degree from Tuskegee University, his MBA from the University of Chicago, and a Master of Science in Information Technology Management from the University of Virginia.
Head of Consumer Lending
Marchesi has been named Head of Consumer Lending and will join Santander Bank on October 13, based in New York. He will manage all aspects of consumer lending, from mortgages to auto lending, responsible for driving the growth of the businesses and their products.
“This newly created role consolidates all of our consumer lending products under one leader to not only simplify our organization but also diversify and digitize the products we offer,” said Habis. “Giancarlo has deep experience in the consumer lending space, and his background in credit risk will only enhance the Bank’s responsible lending.”
Marchesi will join Santander from Wells Fargo where he was a Senior Credit Officer in the auto lending division. He has served in key leadership roles at large financial firms, including Chief Risk Officer of Student Lending and Auto Finance at JPMorgan Chase. He will bring nearly 30 years of banking experience to Santander, with deep knowledge in risk management and retail lending. Marchesi holds a Bachelor of Arts degree in international marketing from Hofstra University and an MBA in finance from New York University.
Chief Marketing Officer
Mathissen will join Santander on November 2 as the Chief Marketing Officer, based in Boston. She will be a strategic partner in driving business growth and customer loyalty. She will also oversee the Customer Experience team.
“Jennifer’s analytical background will help us deliver a best-in-class brand and customer experience through data-driven customer insights and analytics,” said Habis. “She will help us build a modern marketing organization with a strong digital framework where we can effectively tell our story to customers.”
She spent the last two years at CVS Health leading their Enterprise Insights. She will bring to Santander more than 20 years of experience in acquisition marketing, building brands, launching products and developing digital customer experiences honed during her time at Epsilon Agency (formerly Catapult) and McKinsey & Co. She earned a Bachelor of Arts degree in economics from Mount Holyoke College.
Santander Bank, N.A. is one of the country’s largest retail and commercial banks with $89.5 billion in assets. With its corporate offices in Boston, the Bank’s 9,100 employees, 575 branches, more than 2,000 ATMs and more than 2.1 million customers are principally located in Massachusetts, New Hampshire, Connecticut, Rhode Island, New York, New Jersey, Pennsylvania and Delaware. The Bank is a wholly-owned subsidiary of Madrid-based Banco Santander, S.A. (NYSE: SAN) – one of the most respected banking groups in the world with more than 146 million customers in the U.S., Europe, and Latin America. It is overseen by Santander Holdings USA, Inc., Banco Santander’s intermediate holding company in the U.S. For more information on Santander Bank, please visit www.santanderbank.com.
Contacts
Laurie Kight
214.801.6455
Nancy Orlando
617-757-5765
Hurricane Delta is turning north toward the Louisiana coast where it’s expected to slam the shoreline on Friday.
— ABC News: Top Stories